 |
|
|
| |
Efruxifermin in Compensated Cirrhosis due to NASH/MASH: Results from a Randomized, Double-blind, Placebo-controlled, Phase 2b Trial (SYMMETRY)
|
| |
| |
AASLD 2023 nov 10-14
listen to live session
https://www.aasld.org/the-liver-meeting
Efruxifermin is a fusion protein of human IgG1 Fc domain linked to a modified human FGF21 (Fc-FGF21) with balanced in vitro agonist potency at FGFR1c, FGFR2c and FGFR3c14. Efruxifermin is longer acting than most FGF21 analogs, with a 3-3.5-d half-life15. A study in patients with T2D showed improvements in lipoprotein profiles and glycemic control15, which supported investigation of efruxifermin in patients with NASH. This study aimed to test the safety and efficacy of weekly subcutaneous administration for 16 weeks in patients with NASH.
|
| |
|
|
|
|
|
